Abstract:Background: Cardiovascular risk is increased in the anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV). CD4+CD28- T cells are expanded in patients with AAV who are seropositive for cytomegalovirus (CMV), and are associated with increased mortality. CMV seropositivity in other conditions is associated with arterial stiffness, a marker of cardiovascular risk. We assessed whether CD4+CD28- T cells in CMV seropositive patients with AAV are associated with arterial stiffness and whether treatment with valaciclovir reduces this cell population. Methods: In this open-label phase 2 trial, patients were randomised (1:1) by computer to valaciclovir (8 g daily) or no additional treatment for 6 months. Primary outcome was proportion of patients with CMV reactivation. Arterial stiffness (carotid to femoral pulse wave velocity [PWV]) was measured and peripheral blood CD4+CD28- T cells analysed by flow cytometry at baseline and 6 months. CD4+CD28- T-cell interferon γ (IFNγ) secretion was stimulated with CMV lysate. Data are presented as median (IQR). Between-group differences were tested by Mann-Whitney U test and correlations by Spearman's rank. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01633476. Findings: Baseline data are presented from the first 28 patients enrolled, with 6 months' follow-up completed in five treatment and six control patients. More CD4+CD28- than CD4+CD28+ T cells expressed T-bet (83·5% [47·5-89·9] vs 12·9 [4·7-22·2], p<0·0001) and secreted IFNγ after stimulation (14·3% [8·4-26·0] vs 0·8 [0·2-1·3], p<0·0001). CX3CR1, a cell surface marker whose expression is associated with endothelial dysfunction, was only expressed on CD4+CD28- T cells. The proportion of CD4+CD28- T cells correlated with PWV (r=0·408, p=0·035). At 6 months, reduction in proportion of CD4+CD28- T cells was greater in the treatment than in the control group (-1·8% [-5·2 to -0·6] vs 0·5 [-0·8 to 2·5], p=0·044). Interpretation: These preliminary results suggest that CD4+CD28- T cells in AAV are proinflammatory cells with high expression of the fractalkine receptor CX3CR1 that has been implicated in endothelial dysfunction. This cell population is associated with arterial stiffness, and its expansion is attenuated with valaciclovir treatment. This research has important implications, because cardiovascular disease is a major cause of mortality in AAV. Funding: Wellcome Trust, Vasculitis UK.

Anti-Inflammatory Immunomodulatory Activity of Valacyclovir on the in Vitro Activated Mammalian Macrophages

Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial

Exploring the Effectiveness of Acyclovir against Ranaviral Thymidine Kinases: Molecular Docking and Experimental Validation in a Fish Cell Line

Critical Review of Synthesis, Toxicology and Detection of Acyclovir

Molecular Targets of Valeric Acid: A Bioactive Natural Product for Endocrine, Metabolic, and Immunological Disorders

Expression of Toll-like Receptor Genes and Antiviral Cytokines in Macrophage-like Cells in Response to Indole-3-carboxylic Acid Derivative

Acyclovir inhibits channel catfish virus replication and protects channel catfish ovary cells from apoptosis

Medicinal plants and natural compounds against acyclovir-resistant HSV infections

Acellular Human Amniotic Fluid-Derived Extracellular Vesicles as Novel Anti-Inflammatory Therapeutics against SARS-CoV-2 Infection

In Vitro Antiviral and Anti-Inflammatory Activities of N-Acetylglucosamine: Development of an Alternative and Safe Approach to Fight Viral Respiratory Infections

Anti-Human Immunodeficiency Virus Type 1 Microbicide Cellulose Acetate 1,2-Benzenedicarboxylate in a Human In Vitro Model of Vaginal Inflammation

WY14643 Increases Herpesvirus Replication and Inhibits IFNβ Production Independently of PPARα Expression.

Ginkgolic Acid Inhibits Herpes Simplex Virus Type 1 Skin Infection and Prevents Zosteriform Spread in Mice

[Experimental Study of Suppression of Reactivation of Herpes Simplex Virus Type 1 by Cyclooxygenase 2 Inhibitor with Acyclovir].

Anti-infective activity of 2-cyano-3-acrylamide inhibitors with improved drug-like properties against two intracellular pathogens.

CD4+CD28- T-cell expansions in ANCA-associated vasculitis and association with arterial stiffness: baseline data from a randomised controlled trial

Valspodar limits human cytomegalovirus infection and dissemination

Advances and Perspectives in the Management of Varicella-Zoster Virus Infections

Antiviral potential of phenolic compounds against HSV-1: In-vitro study

Valacyclovir or Valganciclovir for Cytomegalovirus Prophylaxis: A Randomized Controlled Trial in Adult and Pediatric Kidney Transplant Recipients

Synthesis, Biological Activity and Decomposition Studies of Amino Acid Phosphomonoester Amidates of Acyclovir